Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Mary J. C. Ludlam"'
Publikováno v:
Biological Imaging, Vol 3 (2023)
High-content screening (HCS) provides an excellent tool to understand the mechanism of action of drugs on disease-relevant model systems. Careful selection of fluorescent labels (FLs) is crucial for successful HCS assay development. HCS assays typica
Externí odkaz:
https://doaj.org/article/eb03fcbb4bcd44a5b57b1916f9cd45fe
Autor:
Daniel J Anderson, Jenni K Durieux, Kyung Song, Ryan Alvarado, Peter K Jackson, Georgia Hatzivassiliou, Mary J C Ludlam
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e22607 (2011)
Oncogenic mutations in the mitogen activated protein kinase (MAPK) pathway are prevalent in human tumors, making this pathway a target of drug development efforts. Recently, ATP-competitive Raf inhibitors were shown to cause MAPK pathway activation v
Externí odkaz:
https://doaj.org/article/089136d7dcfd450691807e2b917fa566
Autor:
Belinda Phipson, Lisa D. Belmont, Chihunt Wong, Erinna F. Lee, Kirsteen J. Campbell, David C.S. Huang, Seong Lin Khaw, Suzanne Cory, Andrew W. Roberts, Stephan P. Glaser, Delphine Merino, Cassandra J. Vandenberg, W.D. Fairlie, Mikara Robati, Daniel Anderson, Philippe Bouillet, Mary J. C. Ludlam, Peng Yue
Publikováno v:
Blood. 119:5807-5816
The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class, navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early clinical studies. Although both drugs avidly bind Bcl-2, Bcl-xL, and Bcl-w in vitro,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c792d5f41c707c21050b361df87f3e0
https://doi.org/10.1182/blood-2011-12-400929
https://doi.org/10.1182/blood-2011-12-400929
Autor:
Mary J. C. Ludlam, Weiru Wang, Nicholas J. Skelton, Angela Oh, Anthony M. Giannetti, Ira Mellman, Daniel Anderson, Till Maurer, Shiva Malek, Melissa A. Starovasnik, Krista K. Bowman, Guowei Fang, Jiansheng Wu, Peter K. Jackson, Borlan Pan, David Stokoe, Benjamin Fauber, Keith Pitts, Lindsay S. Garrenton, Joachim Rudolph
Publikováno v:
Proceedings of the National Academy of Sciences. 109:5299-5304
The Ras gene is frequently mutated in cancer, and mutant Ras drives tumorigenesis. Although Ras is a central oncogene, small molecules that bind to Ras in a well-defined manner and exert inhibitory effects have not been uncovered to date. Through an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3a1748427722c7e861ec3b1bf988fff
https://doi.org/10.1073/pnas.1116510109
https://doi.org/10.1073/pnas.1116510109
Autor:
Wayne J. Fairbrother, Pawan Bir Kohli, Adam R. Johnson, Lisa D. Belmont, Ingrid E. Wertz, Mike Eby, Toru Okamoto, Mark L. Chiu, Cynthia Lam, Somasekar Seshagiri, Jinfeng Liu, Elizabeth Helgason, Jennie R. Lill, Kanan Pujara, Saritha Kusam, Heather Maecker, Vishva M. Dixit, Karen O'Rourke, Mary J. C. Ludlam, Peter K. Jackson, Wendy Sandoval, Erin C. Dueber, Daniel Anderson, Kevin G. Leong, James A. Ernst, David C.S. Huang, Joshua S. Kaminker
Publikováno v:
Nature. 471:110-114
Microtubules have pivotal roles in fundamental cellular processes and are targets of antitubulin chemotherapeutics. Microtubule-targeted agents such as Taxol and vincristine are prescribed widely for various malignancies, including ovarian and breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65722c051c97fcde2008a4449844f5bb
https://doi.org/10.1038/nature09779
https://doi.org/10.1038/nature09779
Autor:
Barbara J. Brandhuber, Hartmut Koeppen, Bijay S. Jaiswal, Marcia Belvin, Somasekar Seshagiri, Mary J. C. Ludlam, Klaus P. Hoeflich, Bonnie Liu, David Stokoe, Daniel Anderson, Guy Vigers, Ivana Yen, Steve Sideris, Kyung Song, Susan L. Gloor, Ryan Alvarado, Ignacio Aliagas, Shiva Malek, Tony Morales, Georgia Hatzivassiliou, Lori Friedman
Publikováno v:
Nature. 464:431-435
Activating mutations in KRAS and BRAF are found in more than 30% of all human tumours and 40% of melanoma, respectively, thus targeting this pathway could have broad therapeutic effects. Small molecule ATP-competitive RAF kinase inhibitors have poten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f431645e11b60af9233521de8ce0fd2f
https://doi.org/10.1038/nature08833
https://doi.org/10.1038/nature08833
Autor:
Terry Lipari, Daniel Kirchhofer, Stuart Bunting, Mary J. C. Ludlam, Rajkumar Ganesan, Alvin Gogineni, Paul Moran, Bu-Er Wang, Wei Li, Hartmut Koeppen, Racquel Corpuz, Wei-Qiang Gao
Publikováno v:
Cancer Research. 69:8395-8402
The transmembrane serine protease hepsin is one of the most highly upregulated genes in prostate cancer. Here, we investigated its tumor-promoting activity by use of a mouse orthotopic prostate cancer model. First, we compared the tumor growth of low
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6355796b266c38f73ed7842e5d5a8383
https://doi.org/10.1158/0008-5472.can-09-1995
https://doi.org/10.1158/0008-5472.can-09-1995
Autor:
Jacob R. Haling, Kyung Song, Daniel Anderson, Shiva Malek, Marcia Belvin, Jocelyn Chan, Joanne Frances Mary Hewitt, Christian Wiesmann, Robert Heald, Klaus P. Hoeflich, Lori Friedman, Steve Price, Mark Merchant, Mary J. C. Ludlam, Georgia Hatzivassiliou, Mark Zak, Huifen Chen, Mark Ultsch, Ariana Peck, Shiuh-Ming Luoh, Christine Orr
Publikováno v:
Nature. 501(7466)
KRAS and BRAF activating mutations drive tumorigenesis through constitutive activation of the MAPK pathway. As these tumours represent an area of high unmet medical need, multiple allosteric MEK inhibitors, which inhibit MAPK signalling in both genot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b5e4a47bc834c601f649fd6d2ae5eb6
https://pubmed.ncbi.nlm.nih.gov/23934108
https://pubmed.ncbi.nlm.nih.gov/23934108
Autor:
Kyung Song, Jenni Durieux, Peter K. Jackson, Ryan Alvarado, Mary J. C. Ludlam, Daniel Anderson, Georgia Hatzivassiliou
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e22607 (2011)
PLoS ONE
PLoS ONE
Oncogenic mutations in the mitogen activated protein kinase (MAPK) pathway are prevalent in human tumors, making this pathway a target of drug development efforts. Recently, ATP-competitive Raf inhibitors were shown to cause MAPK pathway activation v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::127ef4bee902fbd525eaeee578d8e7e5
http://europepmc.org/articles/PMC3150364?pdf=render
http://europepmc.org/articles/PMC3150364?pdf=render
Autor:
Jed Ross, Thijs J. Hagenbeek, Tim C. Cao, Lanlan Yu, Mary J. C. Ludlam, Robby M. Weimer, Franklin Peale, Napoleone Ferrara, Xueping Qu, Marcin Kowanetz, Nina Korsisaari, Nicholas van Bruggen, Zora Modrusan, John G. Lee, Xiumin Wu, Y. Gloria Meng, Joshua S. Kaminker, Hani Bou-Reslan, Dara Y. Kallop, Richard A.D. Carano, Martha Tan
Priming of the organ-specific premetastatic sites is thought to be an important yet incompletely understood step during metastasis. In this study, we show that the metastatic tumors we examined overexpress granulocyte-colony stimulating factor (G-CSF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca80c7124be694c682054afd1ace1fd
https://europepmc.org/articles/PMC3003076/
https://europepmc.org/articles/PMC3003076/
